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OBJECTIVE: This study examined the antimicrobial resistance profile and the prevalence of resistance genes in
Bacteroides spp. and Parabacteroides distasonis strains isolated from children’s intestinal microbiota.
METHODS: The susceptibility of these bacteria to 10 antimicrobials was determined using an agar dilution method.
b-lactamase activity was assessed by hydrolysis of the chromogenic cephalosporin of 114 Bacteriodales strains
isolated from the fecal samples of 39 children, and the presence of resistance genes was tested using a PCR assay.
RESULTS: All strains were susceptible to imipenem and metronidazole. The following resistance rates were
observed: amoxicillin (93%), amoxicillin/clavulanic acid (47.3%), ampicillin (96.4%), cephalexin (99%), cefoxitin
(23%), penicillin (99%), clindamycin (34.2%) and tetracycline (53.5%). b-lactamase production was verified in 92%
of the evaluated strains. The presence of the cfiA, cepA, ermF, tetQ and nim genes was observed in 62.3%, 76.3%,
27%, 79.8% and 7.8% of the strains, respectively.
CONCLUSIONS: Our results indicate an increase in the resistance to several antibiotics in intestinal Bacteroides spp.
and Parabacteroides distasonis and demonstrate that these microorganisms harbor antimicrobial resistance genes
that may be transferred to other susceptible intestinal strains.
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INTRODUCTION
Bacteroides and Parabacteroides species are components of
the colon resident microbiota, and both genera belong to the
order Bacteroidales.1 Species of these genera are often
associated with opportunistic mixed infections, such as
intra-abdominal, obstetric-gynecologic and diabetic foot
infections. In addition, these microorganisms are able to
develop resistance to several antimicrobial drugs.2
Although antibiotics with good activity against these
bacteria are currently available, high frequencies of resis-
tance to some antimicrobials have been reported in several
countries.2,3
Bacteroides and Parabacteroides species produce endogenous
b-lactamases, the most important mechanism of resistance to
b-lactam antibiotics. Bacteroides fragilis is the most frequently
isolated bacteria from infectious diseases, and it exhibits high
levels of resistance to b-lactam drugs4 compared with other
Bacteroidales because of the production of cephalosporinases
and penicillinases encoded by the cepA gene.5
Bacterial resistance to imipenem, ertapenem and merope-
nem arises because of the production of metallo-b-lactamase
(class B) encoded by the cfiA gene, but this resistance is rarely
observed in Bacteroides and Parabacteroides species.6 Strains
harboring ‘‘silent’’ cepA or cfiA genes appear to be resistant to
penicillin, cephalosporin or carbapenem. Conversely, some
B. fragilis strains harboring either cepA or cfiA genes are
susceptible to b-lactams, but after antibiotic pressure, they
become resistant because of an insertion sequence (IS) in the
upstream region of these genes.7
Clindamycin resistance rates have been shown to vary
from 10% to 42% in intestinal Bacteroidales strains world-
wide.3,8 Clindamycin resistance is encoded by the ermF
gene, which confers resistance to macrolides, lincosamides
and streptogramin B via a 23S rRNA mechanism, which
produces the methylases ErmF, EmFS, ErmG and ErmB.9
Metronidazole resistance in anaerobic bacteria appears to
be associated with the nim A to G genes that are transcribed
by promoters located in different IS-producing nitroimida-
zole reductases, which transform 4- or 5-nitroimidazole
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genes to 4- or 5-aminoimidazoles.10 Nitroimidazole resis-
tance in Bacteroides spp. and Parabacteroides distasonis is not
commonly observed. Although non-nim genes associated
with imidazole resistance have been reported, this resis-
tance might be due to an extensive use of metronidazole.
However, the exact mechanism of this resistance remains
undefined.11
The aim of this study was to determine the antimicrobial
resistance profile and the prevalence of resistance genes in
Bacteroides spp. and Parabacteroides distasonis strains isolated
from children’s intestinal microbiota.
METHODS AND MATERIALS
Bacteria
A total of 114 intestinal Bacteroidales samples (66 Bacteroides
fragilis; 14 B. vulgatus; 7 B. uniformis; 7 B. ovatus; 2 B. eggerthii; 2
B. thetaiotaomicron and 16 Parabacteroides distasonis) isolated
from 39 fecal samples from children were evaluated.
Children from 2 children’s hospitals and 2 day care centers
(Sa˜o Paulo, SP, Brazil) were selected for this study, with ages
ranging from 2 months to 8 years old. None of the subjects
received antibiotic therapy prior to sample collection. Fecal
samples were collected from April to December 2000. Stools
were plated onto Bacteroides fragilis-bile-esculin agar and
identified using an established methodology12. The strains
were stored at -80 C˚ in 10% skim milk. This study was
approved by the Ethics Commission of the Instituto de
Cieˆncias Biome´dicas, USP (158/CEP).
Susceptibility Testing
Antimicrobial susceptibility tests were performed using
an agar dilution method in Wilkins & Chalgren agar in
accordance with the recommendations of the Clinical and
Laboratory Standards Institute (CLSI).13 The antibiotics
used were as follows: amoxicillin, ampicillin, cephalexin,
clindamycin and tetracycline (Luper Ind. Farm. Ltd., SP,
Brazil), cefoxitin and imipenem (Merck Sharp & Dohme,
SP), amoxicillin/clavulanic acid (Smithkline Beechman
Brazil Ltd., SP), metronidazole (Aventis Farm. Ltd., SP)
and penicillin (Prodoti Lab. Farm. Ltd., SP). Briefly, media
containing twofold serial dilutions of antimicrobial agents
ranging from 0.25 to 512 mg/ml were inoculated with
1.56105 cfu delivered by a Steers replicator. Media without
antibiotics were used as controls. Plates were incubated in
anaerobic conditions (90% N2/10% CO2) at 37 C˚ for 48 h.
The Minimal Inhibitory Concentration (MIC) was defined as
the lowest concentration of each antimicrobial agent able to
inhibit visible bacterial growth. All tests were performed in
duplicate. The B. fragilis ATCC 43858 was included as a
control in all assays to assess the reliability of the methods.
Determination of b-lactamase activity
Hydrolysis of the chromogenic cephalosporin (Nitrocefin,
Oxoid Ltd., Sa˜o Paulo, SP, Brazil) was used to observe
enzyme production. b-lactamase activity was expressed
semi-quantitatively; negative b-lactamase activity was indi-
cated by a yellow color and positive by a red color. The
penicillin-resistant and b-lactamase-positive strain B. fragilis
ATCC 43858 was used as a control.
Detection of resistance genes by a PCR assay
Bacterial genomic DNA was obtained using an Easy-DNA
kit (Invitrogen do Brasil Ltd., Sa˜o Paulo, SP, Brazil)
according to the manufacturer’s instructions. PCR assays
were used to detect the presence of resistance genes (cfiA,
cepA, ermF, tetQ and nim ) and the insertion sequences (IS942
and IS1186 ) associated with cfiA gene expression.5 DNA
amplifications were performed in volumes of 25 mL contain-
ing 1 X PCR buffer (Invitrogen), 2.5 mM MgCl2, 0.2 mM
dNTP mix (Invitrogen), 0.4 mM of each primer (Invitrogen),
0.5 U of Platinum Taq DNA polymerase (Invitrogen and
10 ng of DNA. Amplifications were performed in a thermal
cycler (PerkinElmer Amp PCR System 9700). Table 1 shows
the PCR conditions, including the genes, primer sequences
and cycles. Amplification products were analyzed by
electrophoresis in a 1% agarose gel (in 1X TBE buffer),
stained with ethidium bromide and photographed under
UV light.
Statistical Analysis
All statistical analyses were performed using GraphPad
InStat statistical analysis software (version 3.05, GraphPad
Software) with a one-way ANOVA. A difference of p#0.05
was considered statistically significant.
RESULTS
All tested strains were susceptible to imipenem and
metronidazole. Cefoxitin was active against 77% of the
tested bacteria. In addition, clindamycin was active against
65.8% of the tested bacteria, combined amoxicillin/clavu-
lanic acid against 52.7%, and tetracycline against 46.4%. All
intestinal Bacteriodales species exhibited antimicrobial resis-
tance ranging from 23% to 99% (Table 2). Most strains (92%)
were able to produce b-lactamases (Table 3). All strains
harbored at least one of the resistance genes evaluated. For
Table 1 - Resistance genes, oligonucleotide sequences
and PCR conditions used to detect target genes
Resistanc
Genes
Oligonucleotide
Sequence 59R39
Amplification
Cycles Reference
cepA TTT CTG CTA TGT CCT GCC C 35 cycles: 5
ATC TTT CAC GAA GAC GGC 94˚C660 sec
52˚C660 sec
72˚C660 sec
cfiA ATG GTA CCT TCC AAC GGG 35 cycles: 5
CAC GAT ATT GTC GGT CGC 94˚C660 sec
56˚C660 sec
72˚C660 sec
IS1186 TGA CCT ACA ACA TCT TCC G 35 cycles: 5
GGT TGT TGA TAA CAA TCA
TCC C
94˚C660 sec
50˚C660 sec
72˚C62 min
IS942 TCC TCA ATA CAT GAG CCG C 35 cycles: 5
GGT TGT TGA TAA CAA TCA
TCC C
94˚C660 sec
50˚C660 sec
72˚C62 min
tetQ ACT TCC GTA ACC GAG AAT
CTG CTG
TAC CGG ATA GAC TTT GGC
TTT TGC
40 cycles:
94˚C660 sec
50˚C660 sec
72˚C640 sec
30
ermF CGG GTC AGC ACT TTA CTA
TTG
GGA CCT ACC TCA TAG ACA
AG
35 cycles:
94˚C630 sec
50˚C630 sec
72˚C62 min
23
nim ATG TTC AGA GAA ATG GGG
CGT AAG CG
GCT TCC TTG CCT GTC ATG
TGC TC
34 cycles:
94˚C660 sec
55˚C660 sec
72˚C630 sec
31
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example, 71 strains (62.3%) harbored the cfiA gene and were
susceptible to imipenem. Moreover, mobile elements were
observed in 2 B. fragilis (IS1186 and IS942) strains, 1 B.
vulgatus (IS1186) strain and 1 P. distasonis (IS942) strain, but
none carried the cfiA gene. The cepA gene was present in 87
(76.3%) of the tested Bacteroidales species, and high
resistance values to some antimicrobials, including cepha-
lexin and penicillin (99%), ampicillin (96.4%), and amox-
icillin (93%), were observed, suggesting the possibility of an
association between the presence of these genes and the
resistance to cephalosporin and penicillin. Out of 39
clindamycin-resistant strains, 31 (79.5%) harbored the ermF
gene. While 91 (79.8%) of the tested strains harbored the
tetQ gene, only 61 (67%) were resistant to tetracycline.
Bacterial strains were susceptible to metronidazole.
However, 9 strains (5 B. fragilis, 1 B. vulgatus, 2 B. uniformis
and 1 P. distasonis) harbored the nim gene. The presence of
resistance genes in all tested Bacteroides and Parabacteroides
strains was statistically significant (p,0.001), and p,0.01
was observed in B. fragilis strains. Table 3 shows the
distribution of the resistance genes in Bacteroides spp. and P.
distasonis.
DISCUSSION
Bacteroidales species are important anaerobe components
of the resident intestinal microbiota, and they are potential
endogenous pathogens. Bacteroides species and P. distasonis
have been shown to induce different infections in humans.2
These intestinal anaerobes are resistant to several penicillins
and cephalosporins,14 but the exact mechanism of this
resistance is unknown.
In this study, a high rate of b-lactamase-producing strains
(92%) was observed in accordance with previous studies.3,15
In addition, some resistant strains can produce b-lactamases
that are encoded by plasmid-borne or chromosomal cepA
genes, and these enzymes are responsible for the increase in
antibiotic resistance.
Most anaerobic bacteria are susceptible to imipenem,4,17
although high rates of resistance to this drug have been
reported.2,14 Moreover, in Bacteroidales the cfiA gene has
been detected at a low rate.16,18,19 In this study, 71 (62.3%) of
the tested strains harbored the cfiA gene, but no imipenem-
resistant strains were observed. Conversely, high detection
rates of the cfiA gene suggest that these strains act as
reservoirs for antibiotic resistance genes, which is in
accordance with the results of Garcia et al.20 The role of
the cfiA gene in these intestinal strains remains unclear, and
further studies are necessary to understand its presence.
Moreover, cfiA-positive Bacteroidales strains did not harbor
either IS942 or IS1186 elements, which has also been
demonstrated by Soki et al.18 and Walsh et al.21 In addition,
strains susceptible to imipenem did not harbor the IS
promoter.
The production of cephalosporinases and penicillinases
encoded by the cepA gene is commonly observed in
Bacteroides spp. and Parabacteroides distasonis.5 In this study,
87 (82.8%) of 105 b-lactamase-producing strains harbored
Table 2 - Resistance profiles of intestinal Bacteroidales species to 8 antibiotics.
Antibiotics* % resistance
**
B. fragilis
(n = 66)
B. vulgatus
(n = 14)
B. uniformis
(n = 7)
B. ovatus
(n = 7)
B. eggerthii
(n = 2)
B.
thetaiotaomicron
(n = 2)
P. distasonis
(n = 16)
Bacteroides spp.
and Parabacteroides
sp. (n = 114)
Amoxicillin 92.4 85.7 100 100 100 100 93.7 93
Amoxicillin/
Clavulanic acid
40.9 42.8 0 85.7 100 100 68.7 47.3
Ampicillin 98.4 92.8 100 100 100 100 87.5 96.4
Cephalexin 100 92.8 100 100 100 100 100 99
Cefoxitin 7.5 0 14.2 0 0 0 12.5 23
Clindamycin 31.8 100 0 71.4 0 0 43.7 34.2
Penicillin 100 92.8 100 100 100 100 100 99
Tetracycline 59 50 28.5 71.4 100 0 43.7 53.5
*Breakpoints used in accordance with CLSI (2007): Amoxicillin (8 mg/mL); Amoxicillin/clavulanic acid (8 mg/mL); Ampicillin (1 mg/mL); Cephalexin (8 mg/mL);
Cefoxitin (32 mg/mL); Clindamycin (4 mg/mL); Imipenem (8 mg/mL); Metronidazole (16 mg/mL); Penicillin (1 mg/mL) and Tetracycline (8 mg/mL).
**All strains were susceptible to imipenem and metronidazole.
***B. fragilis ATCC 43858 was resistant to amoxicillin, ampicillin, cephalexin, clindamycin and penicillin.
Table 3 - Distribution of resistance genes and b-lactamase production in intestinal Bacteroides spp. and P. distasonis.
Species (n) Genes b-lactamase production
cfiA cepA ermF tetQ nim
n˚ (%) n˚ (%) n˚ (%) n˚ (%) n˚ (%) n˚ (%)
B. fragilis (66) 51 (77.2) 53 (80.3) 16 (24.2) 54 (81.8) 5 (7.5) 60 (90.9)
B. vulgatus (14) 5 (35.7) 11 (78.5) 5 (35.7) 7 (50) 1 (7.14) 13 (92.8)
B. uniformis (7) 6 (85.7) 7 (100) 0 (0) 5 (71.4) 2 (28.5) 7 (100)
B. ovatus (7) 1 (14.2) 1 (14.2) 1 (14.2) 6 (85.7) 0 (0) 7 (100)
B. eggerthii (2) 0 (0) 2 (100) 1 (50) 2 (100) 0 (0) 2 (100)
B. thetaiotaomicron (2) 2 (100) 2 (100) 2 (100) 2 (100) 0 (0) 1 (50)
P. distasonis (16) 6 (37.5) 11 (68.7) 6 (37.5) 15 (93.7) 1 (6.25) 15 (93.7)
TOTAL (114) 71 (62.3) 87 (76.3) 31 (27) 91 (79.8) 9 (7.8) 105 (92)
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the cepA gene, suggesting that some strains were able to
produce this enzyme using mechanisms other than the cepA
gene.
Most b-lactamase-producing strains were susceptible to
cefoxitin, with a resistance rate of only 23% (Table 2). These
data are supported by previously published studies.3,8
Moreover, the combination of amoxicillin and clavulanic
acid did not show good activity against 47.3% of the tested
strains, in accordance with Wybo et al.3 and Roberts et al.17
Clindamycin is a semi-synthetic drug used extensively in
the treatment of anaerobic infections.22 However, bacterial
resistance to this drug has significantly increased over the
last two decades. In this study, 34.2% of strains were
observed to be clindamycin resistant, in accordance with
Betriu et al.14 Intestinal Bacteroidales strain resistance rates to
clindamycin have been shown to vary between countries
from 39% to 41%.3,4,16
The ermB, ermF, ermG, and ermS genes are the most
common determinants of genetic resistance in intestinal
Bacteroidales strains.23 Of the 39 (34.2%) clindamycin-
resistant strains in this study, only 10 harbored the ermF
gene. Bacterial resistance to clindamycin can arise because
of the presence of the ermB or ermG genes24 or by other
mechanisms, such as efflux pumps.25 In addition, clinda-
mycin resistance among Bacteroidales species has increased
in several countries.26,27 This alarming resistance to clin-
damycin among Bacteroides spp. and P. distasonis makes its
use unacceptable for the empiric therapy of severe anaerobic
infections.
Tetracycline is one of the most widely used antibiotics
worldwide, but its use has decreased because of the high
resistance rates observed in various microorganisms,
including Bacteroides spp. and Parabacteroides distasonis.16
Efflux pumps, ribosome protection and tetracycline mod-
ification are the main mechanisms of bacterial resistance to
tetracycline. However, ribosome protection appears to be
the most widespread in nature.28 The tetQ and tetM genes
encoding the ribosome-protecting proteins are often asso-
ciated with conjugative transposons.29 In this study, 53.5%
of the tested strains were resistant to tetracycline, and
among the 91 (79.8%) of 114 total strains harboring the tetQ
gene, 61 (67%) showed resistance to tetracycline. This result
suggests that these bacteria may become resistant either by
activating other genes, such as tetM, tetK, tetL and tetO, or by
another mechanism of resistance that remains to be clarified.
All tested strains were susceptible to metronidazole in
accordance with Odou et al.4 However, other studies have
noted an increase in the rate of resistance to metronida-
zole.3,11 In this study, only 9 (7.8%) strains harbored the nim
gene. Metronidazole resistance associated with nim has been
described in Bacteroides spp. and Parabacteroides distasonis
strains from different geographic regions.11 However,
resistance to metronidazole does not depend on the
presence of nim genes, and the true role of these genes is
not yet clear. In addition, nim-negative strains expressing
high levels of resistance to metronidazole have been
sporadically isolated, suggesting an additional mechanism
of resistance11 and also justifying additional studies
concerning the susceptibility profile and detection of nim
genes.
Few studies have addressed antimicrobial susceptibility
profiles and the detection of resistance genes in intestinal
anaerobic resident microbiota in Brazil, especially with a
focus on children. Careful monitoring of antimicrobial
resistance and detection of these genes might be of interest,
verifying the presence and spread of intestinal Bacteriodales
strains with resistance markers to different antimicrobials in
different countries.
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